论文部分内容阅读
目的对比预混双相门冬胰岛素30与口服药+预混人胰岛素30R治疗对初诊2型糖尿病患者血糖控制及其对胰岛β细胞功能的影响。方法对两组分别为30例的初诊2型糖尿病患者,分别予以门冬胰岛素30及口服药+预混人胰岛素30R治疗,治疗时间为8周,检测治疗前后的血糖、糖化血红蛋白(HbA1c)、空腹及餐后2 h C肽等指标。结果两组治疗前后血糖、胰岛β细胞功能等方面比较差异有统计学意义,门冬胰岛素30较口服药+预混人胰岛素30R治疗组能更好的降低HbA1c的水平。结论对初诊2型糖尿病患者,每日给予3次皮下注射门冬胰岛素30强化治疗能更好地控制血糖,改善和恢复胰岛β细胞功能。
Objective To compare the effect of premixed biphasic insulin aspart 30 with oral medication + pre-mixed insulin 30R on glycemic control and pancreatic β-cell function in newly diagnosed type 2 diabetic patients. Methods Thirty patients with newly diagnosed type 2 diabetes mellitus were treated with insulin aspart 30 and oral drug plus pre-mixed insulin 30R respectively for 8 weeks. The levels of blood glucose, HbA1c, Fasting and postprandial 2 h C peptide and other indicators. Results Before and after treatment, there were significant differences in blood glucose, pancreatic β-cell function between the two groups. Aspart 30 could reduce the level of HbA1c better than the oral medication + pre-mixed insulin 30R treatment group. Conclusions For patients with newly diagnosed type 2 diabetes, administration of insulin aspart 30 subcutaneously three times per day can better control blood glucose and improve and restore islet β-cell function.